Median progression-free survival was significantly longer in the trebananib group than in the placebo group ( @ months -LSB- @-@ -RSB- vs @ months -LSB- @ % CI @-@ -RSB- , respectively , hazard ratio @ , @ % CI @-@ , p < @ ) .